Phase II Alliances Command the Most Interest
Executive Summary
Biotechs have always relied on four sources of financing: venture capital, public equity, M&A, and alliances. But of these four financing "legs", only one remains strong: alliances. There's no question that average potential deal values-a combination of up-front fees and pre-commercialization money-are increasing nicely. But while the mean value of early-stage deals has remained steady, deal values for both Phase II and Phase III /NDA-stage compounds have continued to climb.
You may also be interested in...
Pharmaceutical Strategic Outlook: The Trouble with Alliances
At Windhover's March 2008 Pharmaceutical Strategic Outlook meeting one overriding theme was an alliance paradox: values continue to rise and deals provide an increasingly important source of funds for biotechs, yet public investors don't seem to like these deals. Plus: a discussion of big-pharma outlicensing and the importance of CFOs in pharma strategy.
The Value of Proof-Of-Concept
Big Pharma's unprecedented spending levels in licensing continue. But some recent deals suggest the real linchpin of licensing value is proof-of-concept in humans.
UK Government Wants To Work With Industry To Identify OTC Switch Candidates
The UK's medicines regulator, MHRA, alongside other government agencies, intends to work together with manufacturers to identify Rx-to-OTC switch candidates. Switch criteria might include “different strength medicines to those available today, combination formulations, or medicines manufacturers already offer without prescriptions in other countries,” NHS England says, in its recently published “Delivery plan for recovering access to primary care.”